Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative
Anticoagulant Citrate Phosphate Dextrose (cpd) And As-5 Red Cell Preservative
Terumo Corporation
Human Prescription Drug
NDC 53877-007Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative also known as Anticoagulant Citrate Phosphate Dextrose (cpd) And As-5 Red Cell Preservative is a human prescription drug labeled by 'Terumo Corporation'. National Drug Code (NDC) number for Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative is 53877-007. This drug is available in dosage form of Kit. The names of the active, medicinal ingredients in Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative drug includes . The currest status of Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative drug is Active.
Drug Information:
| Drug NDC: | 53877-007 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Imuflex Wb-sp Blood Bag System With Integral Whole Blood Leukocyte Reduction Filter (saving Platelets) With Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol (as-5) Red Cell Preservative |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Anticoagulant Citrate Phosphate Dextrose (cpd) And As-5 Red Cell Preservative |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Terumo Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Kit |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | INTRAVENOUS
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 15 Dec, 2010 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | BN880217 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Terumo Corporation
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 53877-007-41 | 15 BAG in 1 CASE (53877-007-41) / 1 KIT in 1 BAG * 70 mL in 1 BAG * 111 mL in 1 BAG | 15 Dec, 2010 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Imuflex wb-sp blood bag system with integral whole blood leukocyte reduction filter (saving platelets) with diversion blood sampling arm anticoagulant citrate phosphate dextrose (cpd) and optisol (as-5) red cell preservative anticoagulant citrate phosphate dextrose (cpd) and as-5 red cell preservative anticoagulant citrate phosphate dextrose (cpd) anticoagulant citrate phosphate dextrose (cpd) trisodium citrate dihydrate anhydrous citric acid sodium phosphate, monobasic, unspecified form phosphate ion sodium cation dextrose monohydrate anhydrous dextrose anhydrous citric acid anhydrous citric acid water optisol red cell preservative as-5 red cell preservative sodium chloride sodium cation dextrose monohydrate anhydrous dextrose mannitol mannitol adenine adenine water
Indications and Usage:
1. indications and usage 1.1. read these instructions carefully before use. 1.2. rx only. 1.3. intended for the collection, processing and preservation of whole blood and blood components. not intended for direct intravenous infusion. 1.4. for the collection of 500 ml ±10% whole blood. 1.5. integral diversion blood sampling arm is intended to divert and obtain donor samples for laboratory testing prior to collection of the whole blood unit. 1.6. integral filter unit intended for leukocyte reduction of whole blood up to 8 hours after blood collection when whole blood is stored at ambient temperature. 1.7. for further processing, use standard component processing techniques.
Warnings:
5. warnings and precautions 5.1. rx only. 5.2. do not use unless solutions are clear and free from particulates. 5.3. always inspect the blood bag set for leaks before use. 5.4. avoid excessive heat and direct sunlight. protect from freezing. 5.5. recommended storage conditions: room temperature (15-30°c/59-86°f). 5.6. it is normal to have condensation in the blister packaging. if the amount of moisture is greater than expected, check for leaks from the fluid-filled components of the blood bag set. 5.7. use aseptic techniques. 5.8. do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose. 5.9. do not touch needle after removing the needle cover. 5.10. do not collect donor test samples until the tubing between the "y" and the diversion pouch is permanently sealed. 5.11. discard the diversion blood sampling arm and phlebotomy needle/donor tubing according to institutional standard operating pro
Read more...cedures. 5.12. the ageless® oxygen absorber packet, (mitsubishi gas chemical) contained in this package absorbs oxygen and generates heat on removal. do not open and handle it with care. 5.13. dispose of the ageless packet with the blister tray. 5.14. do not dispose the ageless packet with wastes containing volatile or flammable materials. 5.15. due to possible exposure to infectious agents in the handling of blood, take adequate precautions at all times to prevent exposure to and transmission of such agents. follow your institution's standard operating procedures.
Dosage and Administration:
2. dosage and administration 2.1. to open blister package, peel cover film back 4/5 of its length. 2.2. prepare the blood bag following your institution's standard operating procedures. 2.2.1. materials needed : evacuated blood collection tubes (glass or plastic) 2.3. make a loose knot in the donor tubing below the "y" and cliktip® (inline closure device) unless alternate methods are used to seal the tubing at the end of collection. 2.4. temporarily clamp donor tubing between the phlebotomy needle and the "y". 2.5. suspend the collection bag as far as possible below the donor's arm. 2.6. apply blood pressure cuff or tourniquet to donor's arm. disinfect site of phlebotomy. if blood pressure cuff is used, inflate to approximately 60 mmhg. 2.7. remove the needle cover and perform phlebotomy. remove the temporary clamp on the donor tubing to permit blood flow into the diversion blood sampling arm pouch. 2.7.1. caution: do not touch the needle after removing the needle cover. 2.8. secure
Read more... the needle safety device in place following the device instructions provided on the reverse side. 2.9. secure donor tubing to donor's arm. 2.10. position the diversion pouch with the notches up and the tube holder/luer adapter assembly down. when the level of blood in the pouch is approximately in line with the notches, the diversion pouch is full. (fig. 2a) 2.10.1. note: the approximate fill volume of the pouch at the notches is 35 ml. 2.11. permanently seal the tubing between the "y" and the diversion pouch to maintain a closed system using an aluminum clip or a tube sealer approved for use with tubing connected to a donor (fig. 2b). 2.11.1. caution: do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose. 2.12. to initiate blood flow into the collection bag, break the cliktip between the "y" and the collection bag. 2.13. to avoid clot formation, collect samples as soon as possible from the diversion pouch as follows (fig. 2b). 2.13.1. caution: do not collect donor test samples until the tubing between the "y" and the diversion pouch is permanently sealed. 2.13.2. break the cliktip in the tubing below the pouch to open the pathway for sampling. (fig. 2b) 2.13.3. position the diversion pouch with the notches up and the tube holder/luer adapter assembly downward. assure that any air in the pouch is at the top and will not enter the blood collection tubes. 2.13.4. open the tube holder lid and insert blood collection tube firmly into the tube holder; when full, remove sample tube from holder. repeat to collect additional samples. 2.13.5. note: the pouch may be removed after the donor test samples are collected. a second seal must be made between the diversion pouch and the permanent seal prior to removing the pouch. 2.14. mix blood with anticoagulant in the collection bag and continue to mix at several intervals during collection and immediately after collection. if using an automated mixer, follow manufacturer's instructions. 2.15. collect labeled volume of blood 500 ml ±10%. 2.16. when the desired amount of blood has been collected, seal the tubing or tighten the loose knot (white knot) prepared in step 2.3. make a second seal between the first seal or knot and the "y". various methods may be used to seal tubing. 2.17. release pressure on the donor's arm and remove the needle into the needle safety device following the device instructions provided on the reverse side. sever the donor tubing between the two seals previously made below the cliktip and "y". 2.17.1. caution: discard the diversion blood sampling arm and phlebotomy needle/donor tubing according to institutional standard operating procedures. 2.18. seal and remove donor tubing from collection bag or strip donor tubing as follows: 2.18.1. to obtain a quality control prefiltration sample, strip blood from donor tubing into collection bag, mix well, and allow tubing to refill; repeat once. to prevent the blood from clotting in the tubing, work quickly as possible. leave an adequate length of tubing containing the well-mixed anticoagulated whole blood attached to the collection bag. 2.18.2. or, to maximize collection recovery, strip the tubing, mix well and seal tubing close to the collection bag without refilling. to prevent the blood from clotting in the tubing, work quickly as possible. remove tubing from collection bag. 2.19. the blood filtration is executed according to the following operation. (see fig.3 and fig.4 ) 2.19.1. note: wait 1 hour after collection before filtering. filtration can be accomplished when blood is stored at room temperature for up to eight hours after collection. 2.19.2. note: the band guides used to bundle the coiled tubing to prevent entanglement during shipping should be removed prior to filtration (not depicted). 2.20. mix the unfiltered whole blood unit by inverting the collection bag #1 (pre-filter bag) several times. 2.21. hang the collection bag #1, and extend the filtration set to 85 ± 2.5 cm or 33.5 ± 1 inch. verify that the filter is vertical and ensure all tubing is freely suspended. position and support bags #2-4 on a flat surface (fig. 4). 2.21.1. note: this distance is measured from the outlet of the collection bag to the position of the supported bags as indicated in fig. 4. 2.21.2. note: verity tubing has been removed from the tube guides and extends freely. 2.22. break the cliktip at the outlet of the collection bag #1, and start filtration. 2.22.1. caution: do not squeeze the collection bag during filtration. 2.22.2. caution: do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood. 2.22.3. caution: if for any reason whole blood passes through the one-way valve, stop filtration immediately and consider the product as non-leukocyte reduced. 2.23. filtration ends when the collection bag is empty or blood flow has stopped. close the white clamp above the filter. 2.24. expel air through the bypass line and back into the empty collection bag #1 by holding the primary bag #2 upright so that the air will be closest to the ports. gently squeeze the primary bag containing the leukoreduced whole blood until filtered blood reaches the "y" below the filter. to ensure ease of air removal ensure primary bag #2 is below the filter outlet. 2.25. open the white clamp. 2.26. recovery of filtered whole blood is complete when the collection bag and the inlet side of the filter have drained or blood flow has stopped. close the white clamp. 2.27. seal the tubing as close as possible to the "y" below the filter and properly dispose of the filter and collection bag #1. 2.28. strip the post filter tubing into the primary bag #2, mix well, and allow tubing to refill; repeat once. make an appropriate number of segments of anticoagulated blood for testing by sealing on or near the x marks. leave segments attached to the filtered whole blood unit. 2.29. the time between whole blood collection and component separation may vary depending on both the blood bag system and processing options selected. 2.29.1. note: platelets should be separated from the red blood cells within 8 hours of blood collection. 2.29.2. note: fresh frozen plasma should be separated from the red blood cells and placed in a freezer at â18ºc or colder within 8 hours of collection. 2.29.3. note: optisol should be added to the red blood cells immediately after removal of the plasma. if plasma is not separated from the red blood cells within 8 hours, optisol may be added within 72 hours of collection if whole blood is refrigerated. 2.29.4. note: other plasma components may be prepared following approved regulations and standards. 2.30. follow your institution's standard component processing procedures to prepare components. 2.31. centrifuge filtered whole blood unit to separate red blood cells from platelet rich plasma. 2.32. break the cliktip of primary bag #2 and transfer leukocytes-reduced platelet rich plasma into xt-612 platelet bag #3. clamp the transfer tubing on the platelet bag. 2.33. break the cliktip of the optisol bag #4 and drain contents into primary bag #2 containing red blood cells. seal tubing of primary bag in two places, and cut between seals and separate from platelet and optisol bags. 2.33.1. note: empty optisol bag is used for further component preparation. 2.34. invert the red blood cell â optisol mixture several times to assure the final product is well suspended. 2.35. store as-5 red blood cells, leukocytes reduced between 1-6°c for up to 42 days. 2.35.1. note: whole blood or red blood cells in cpd may be stored for up to 21 days at 1-6°c. 2.36. store platelets, leukocytes reduced between 20-24°c, maintaining a continuous gentle agitation, for up to 5 days in xt-612 bag. fig. 1 fig. 2a/2b fig. 3 fig. 4 figure figure figure figure figure
Dosage Forms and Strength:
3. dosage forms and strengths 3.1. 70 ml citrate phosphate dextrose (cpd) anticoagulant usp for collection of 500 ml whole blood. each 70 ml contains 1.79 g dextrose (monohydrate) usp, 1.84 g sodium citrate (dihydrate) usp, 209 mg citric acid (anhydrous) usp, 156 mg monobasic sodium phosphate (monohydrate) usp. 3.2. 111 ml optisol red cell preservative solution. each 111 ml contains 974 mg sodium chloride usp, 1.00g dextrose (monohydrate) usp, 583 mg mannitol usp, 33.3 mg adenine usp.
Description:
11. description / product specifications 11.1. this blood bag system includes a 16 gauge à 1 1/2 inch (1.60 à 38 mm) needle with needle cover and a 500ml (nominal capacity 600ml) collection bag containing 70ml citrate phosphate dextrose (cpd) anticoagulant. the quadruple blood bag set has one integrally attached empty primary bag, one empty xt-612 5 day platelet bag, and one satellite bag containing 111 ml optisol red cell preservative solution. 11.2. blood bag codes ending in a6 are the collection set with an integral diversion blood sampling arm for obtaining donor samples prior to collection of the whole blood unit. 11.3. blood bag codes ending in a6 also include a donorcare® needle guard pre-attached to the donor tubing. donorcare needle guard device instructions are provided on the reverse side. 11.4. the blood bag collection set is made of pvc (polyvinyl chloride with dehp plasticizer). 11.5. the blood bag has no components made of natural rubber latex. 11.6. tubing internal diameter (id) nominal 3.0 mm. 11.7. tubing outer diameter (od) nominal 4.4 mm. 11.8. tubing line maximum 16 segments available.
How Supplied:
16. how supplied/storage and handling 16.1. single use only. 16.2. sterile and non-pyrogenic fluid path. sterilized by steam. opacity of the blood bag system may be observed. this is due to moisture absorption during the sterilization process. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. 16.3. a material safety data sheet (msds) is not required for this product. 16.4. recommended storage conditions: room temperature (15-30°c/59-86°f). 16.5. avoid excessive heat and direct sunlight. protect from freezing. 16.6. to open blister package, peel cover film back 4/5 of its length. 16.7. after opening, the blood bag system may be stored at room temperature for 7 days, or it may be stored for 30 days in the blister package after returning the cover film to the original position and sealing with tape to prevent possible loss of moisture. 16.8. blood bags in the unopened blister package may be used through the last day of the month
Read more...and year as indicated on the original manufacturer's packaging. 16.9. the ageless packet contained in this package absorbs oxygen and generates heat on removal. do not open and handle it with care. 16.10. dispose of the ageless packet with the blister tray. 16.11. do not dispose the ageless packet with wastes containing volatile or flammable materials. 16.12. for the quadruple blood bag set, code bb*lgq506a6 is supplied 15/case.
Spl Patient Package Insert:
Procedure for use of donorcare ® needle guard this device is for use by trained individuals. intended use the donorcare® needle guard is incorporated onto the donor tubing to shield the needle immediately after withdrawal from the donor. single use only. preparation 1. move the donorcare on the tubing ensuring that it slides easily and the arrow is pointing toward the needle hub. 2. ensure that the three lock points on the donorcare are locked closed. whole blood collection 3. perform the phlebotomy as per your institution's standard operating procedures. 4. slide the donorcare over the needle hub so that it covers approximately one half to two thirds of the needle hub. 5. stabilize the donorcare to the arm by placing a piece of tape over the front end so that the tape does not extend over the front of the donorcare. withdrawal of needle important the donorcare must be held stationary while the needle is withdrawn into it. caution the needle must be fully shielded by donorcare to
Read more... prevent accidental injury. 6. hold gauze over the venipuncture site with finger tips without exerting pressure. hold the sides of the donorcare near the front with the index finger and thumb of the same hand. 7. with the other hand, hold the donor tubing close behind the donorcare. note: a hemostat may be placed on the tubing behind the donorcare when the blood collection is complete. this will help to prevent blood drops from forming. 8. pull tubing smoothly and swiftly with one motion until the needle is locked in place inside the donorcare. 9. confirm that the needle is locked by: a. listening for two 'clicks' as the needle is drawn into donorcare. b. if the clicks are not heard as the needle is drawn into the donorcare, continue to pull firmly on the tubing to assure needle is fully withdrawn into donorcare. 10. visually check that the needle is fully shielded by donorcare before removing from the donor's arm. 11. remove the tape from the donorcare and arm. 12. apply pressure to the gauze covering the venipuncture site. warning do not place fingers at the opening of donorcare after removal from the donor's arm. difficult phlebotomy (examples may include: slow blood flow, deep or fine vein, steep angle) it may be necessary to delay placing the donorcare over the needle hub until the end of the blood collection. in such situations: leave the donorcare on the tubing behind the needle hub. at the end of the blood collection carefully remove the tape from the needle hub and slide the donorcare over the hub so that it covers approximately one half to two thirds of the needle hub. withdraw the needle into the donorcare as stated in steps 6. through 12. above.
Package Label Principal Display Panel:
Tray/case label imuflex® wb-sp blood bag system with integral whole blood leukocyte reduction filter (saving platelets) with diversion blood sampling arm® cpd with optisol® red cell preservative solution for collection of 500ml of blood each unit consists of a collection bag containing 70ml of anticoagulant cpd solution, with a satellite bag containing 111ml of optlsol red cell preservative solution. each 70ml anticoagulant cpd solution usp contains 1.79g dextrose (monohydrate) usp, 1.84g sodium citrate (dihydrate) usp, 209mg citric acid (anhydrous) usp, 156mg monobasic sodium phosphate (monohydrate) usp. each 111ml optisol red cell preservative solution contains 974mg sodium chloride usp, 1.00g dextrose (monohydrate) usp, 583mg mannitol usp, 33.3mg adenine usp. sterile, non-pyrogenic fluid path. do not use unless solutions are clear. code lot no. expiry unit(s) donor needle 16g x 1 1/2Ë (1.60 x 38mm) rx only recommended storage: room temperature (15-30°c/59-86°f). avoid excessive heat. protect from freezing. after opening, the blood bag system may be stored at room temperature for 7 days, or it may be stored for 30 days in the blister package after returning the cover film to the original position and sealing with tape to prevent possible loss of moisture. see instructions for use. manufactured by : terumo corporation tokyo, japan ® : registered trademark issued 01/06 b-4-hs6-a2 1 place label here imuflex wb-sp blister-case label text